By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators publish new report on Biotechnology. According to news reporting originating from London, United Kingdom, by NewsRx correspondents, research stated, "A Severe combined immunodeficiency (SCID) arises from different genetic defects associated with lymphocyte development and function and presents with severe infections. Allogeneic hematopoietic stem cell transplantation is an extremely effective way of restoring immunity in these individuals."
Our news editors obtained a quote from the research from Great Ormond St. Hospital Sick Children, "Numerous multicenter studies have identified the factors determining successful outcome, and survival for SCID has shown great improvement. Advances in understanding the genetic basis of disease also mean that we increasingly tailor transplant protocols to the specific SCID form. Wherever possible, we attempt to transplant SCID patients without the use of cytoreductive conditioning, but it is clear that this is only successful for specific SCID forms and, although survival is good, in specific patients there are ongoing humoral defects. We aim to use matched related and unrelated donors (including cord blood) whenever possible and have limited the use of mismatched haploidentical donors. The development of autologous hematopoietic stem cell gene therapy provides another treatment of the X-linked and adenosine deaminase-deficient forms of SCID, and we discuss how we have integrated gene therapy into our treatment strategy."
According to the news editors, the research concluded: "These developments together with the advent of universal newborn screening for SCID should allow for a highly favorable outcome for this otherwise lethal condition."
For more information on this research see: How I treat severe combined immunodeficiency. Blood, 2013;122(23):3749-3758. Blood can be contacted at: Amer Soc Hematology, 2021 L St NW, Suite 900, Washington, DC 20036, USA. (American Society of Hematology - www.hematology.org/; Blood - bloodjournal.hematologylibrary.org/)
The news editors report that additional information may be obtained by contacting H.B. Gaspar, Great Ormond St Hosp Sick Children, Dept. of Blood & Marrow Transplantat, London WC1N 3JH, United Kingdom. Additional authors for this research include W. Qasim, E.G. Davies, K. Rao, P.J. Amrolia and P. Veys (see also Biotechnology).
Keywords for this news article include: Biotechnology, London, Europe, Newborn, Genetics, Treatment, Gene Therapy, United Kingdom, Bioengineering, Infant Diseases, Severe Combined Immunodeficiency
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC